Zhang X. Anti-retroviral drugs: current state and development in the next decade.
Acta Pharm Sin B 2018;
8:131-136. [PMID:
29719774 PMCID:
PMC5925449 DOI:
10.1016/j.apsb.2018.01.012]
[Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2017] [Revised: 01/12/2018] [Accepted: 01/21/2018] [Indexed: 01/05/2023] Open
Abstract
The pace of discovery of new antiretroviral (ARV) drugs has slowed, although the efficacy and safety of once-daily fixed dose combinations have been extensively investigated. Several traditional ARV drugs remain in phase III clinical trials. This review summarizes current information on ARV drugs in phase III clinical trials and focuses on the development of ARV drugs in the next decade.
Collapse